Evidence map›Paper›PMID 36781879›Full record

ArticleNPJ vaccines2023

Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19.

Paulina Kaplonek, Deniz Cizmeci, Jessica Shih-Lu Lee, Sally A Shin, Stephanie Fischinger, Philipe Gobeil, Stéphane Pillet, Nathalie Charland, Brian J Ward, Galit Alter

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Paulina Kaplonek *Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Deniz Cizmeci *Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-3231-7726
Jessica Shih-Lu LeeRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Sally A ShinRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-9306-2264
Stephanie FischingerRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Philipe GobeilMedicago Inc., Quebec City, QC, Canada.
Stéphane PilletMedicago Inc., Quebec City, QC, Canada.
Nathalie CharlandMedicago Inc., Quebec City, QC, Canada.
Brian J WardMedicago Inc., Quebec City, QC, Canada. wardb@medicago.com.
Galit AlterRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA. galter@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-7680-9215

Funding

COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,75N93019C00052 · NIAID · UNIVERSITY OF GEORGIA · PI ROSS, TED · 2019 to 2025
$74.6M
Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Kristian Graugaard Andersen · 2018 to 2026
$32.0M
Demystifying the antiviral activity of the IgG3+ antibody responseR37AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2015 to 2022
$5.8M
Immunologic Signatures of SARS-CoV-2 Vaccination and DiseaseU01CA260476 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2020 to 2024
$3.7M
SARS-CoV-2 Variant TestingR01AI146785 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2020 to 2024
$3.3M
CHLAMYDIA PNEUMONIAE AND MACROPHAGES IN ATHEROSCLEROSISR01AI042790 · NIAID · UNIVERSITY OF WISCONSIN MADISON · PI BYRNE, GERALD IRWIN · 1999 to 2003
$983k
NCI NIH HHS U01 CA260476NIAID NIH HHS 75N93019C00052NIAID NIH HHS R01 AI042790NIAID NIH HHS R01 AI146785NIAID NIH HHS R37 AI080289NIAID NIH HHS U19 AI135995
6 · The paper itself

Abstract

Despite the success of existing COVID-19 vaccine platforms, the persistent limitations in global deployment of vaccines and waning immunity exhibited by many of the currently deployed vaccine platforms have led to perpetual outbreaks of SARS-CoV-2 variants of concern. Thus, there is an urgent need to develop new durable vaccine candidates, to expand the global vaccine pipeline, and provide safe and effective solutions for every country worldwide. Here we deeply profiled the functional humoral response induced by two doses of AS03-adjuvanted and non-adjuvanted plant-derived Coronavirus-like particle (CoVLP) vaccine candidate from the phase 1 clinical trial, at peak immunogenicity and six months post-vaccination. AS03-adjuvanted CoVLP induced robust and durable SARS-CoV-2 specific humoral immunity, marked by strong IgG1antibody responses, potent FcγR binding, and antibody effector function. Contrary to a decline in neutralizing antibody titers, the FcγR2A-receptor binding capacity and antibody-mediated effector functions, such as opsonophagocytosis, remained readily detectable for at least six months.

Identifiers

PMID36781879
PMCPMC9924894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.